NeoGenomics, Inc. (NEO)

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group Announces 47th Annual NEO: The Conference for Neonatology.

Shares of NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) have been assigned an average rating of "Hold" from the fourteen research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation, five have given a buy recommendation and

NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.

NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript

NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.

NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.

NeoGenomics, Inc. (NASDAQ: NEO - Get Free Report) has received a consensus recommendation of "Hold" from the thirteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have given a hold recommendation, five have given a buy recommendation and one has given

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.

NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration.

Campbell and CO Investment Adviser LLC lowered its position in NeoGenomics, Inc. (NASDAQ: NEO) by 60.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 30,487 shares of the medical research company's stock after selling 46,288 shares during

NEW YORK--(BUSINESS WIRE)---- $BETR #AI--Better Home & Finance Holding Company (NASDAQ: BETR) (“Better.com”), the leading AI-native home finance company and the first fintech to fund more than $100 billion in loan volume, celebrates the one-year anniversary of its partnership with NEO Home Loans (“NEO”) and proudly announces significant gains in production efficiency and cost to originate through its advisor-led distributed retail channel, NEO powered by Better. This monumental growth demonstrates the me.

NeoGenomics (NASDAQ: NEO - Get Free Report) and AstraZeneca (NASDAQ: AZN - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Insider and Institutional Ownership 98.5% of NeoGenomics shares are held

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript